Global /United States /Healthcare /Biotechnology /LGVN

Longeveron Inc.

LGVN

• NASDAQ: LGVN • Delayed

0.8655USD -2.1%

As of 13 June 2026, Longeveron Inc. has a market cap of $25.34M USD, ranking #35410 globally and #4870 in the United States. It ranks #3199 in the Healthcare sector, and #617 in the Biotechnology industry.

Global Rank

35410

Country Rank

4870

Sector Rank

3199

Industry Rank

617

Key Stats

Market Cap

$25.34MUSD

Enterprise Value

$21.58MUSD

Revenue (TTM)

$1.2MUSD

EBITDA (TTM)

-$22.06MUSD

Net Income (TTM)

-$22.7MUSD

PS Ratio

21.2

PB Ratio

3.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Stephen Willard open_in_new

Employees

Founded

2014

IPO

12 Feb 2021

Website

longeveron.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.1%	-15%	-5.4%	46%	-6.3%	72%	-47%	-97%	-99%

News

LGVN Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	LGVN Longeveron Inc Ordinary Shares - Class A ISIN: US54303L2034 Shares Out.: Shares Outstanding: 30.149M¹ Shares Float: 26.045M² TV: TradingView: NASDAQ: LGVN SA: Stock Analysis: NASDAQ: LGVN YF: Yahoo Finance: LGVN GF: Google Finance: NASDAQ: LGVN NQ: NASDAQ: LGVN BA: Barron's: LGVN MS: Morningstar: XNAS: LGVN	0.8655 USD	TV: TradingView: NASDAQ: LGVN SA: Stock Analysis: NASDAQ: LGVN YF: Yahoo Finance: LGVN GF: Google Finance: NASDAQ: LGVN NQ: NASDAQ: LGVN BA: Barron's: LGVN MS: Morningstar: XNAS: LGVN

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Longeveron Inc.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 720K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 631K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 109K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 104K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 99K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 71K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 189K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 177K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 167K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 167K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 111K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 101K%	-	Germany

chevron_leftBack